“…By detecting and analyzing circulating targets in body fluids (blood, urine, and saliva), it can provide comprehensive physiopathological information in real time in a noninvasive manner. − Compared to traditional tissue biopsy, liquid biopsy breaks through the constraints of time and space to screen for cancer in asymptomatic patients and allows for repeat blood collection, providing insight into the evolutionary dynamics of cancer . MicroRNAs (miRNAs), as a class of short noncoding RNAs with a length of approximately 18 to 25 nucleotides, are very promising biomarkers in liquid biopsy strategies. , MiRNAs have been demonstrated that their expression has a critical role in biological processes such as cancer initiation and tumor progression; moreover, they can remain stable in the blood. − However, many studies have revealed that a series of miRNAs can better distinguish cancer types and status than a single miRNA. − Moreover, it is very necessary to detect miRNAs along with the endogenous control to alleviate the biases in miRNA expression levels caused by individual physiological diversity and technical discrepancies, which results from sample collection and RNA extraction. , Currently, techniques including Northern blotting, real-time quantitative PCR (RT-qPCR), and microarray have been successfully applied for miRNA detection. Nevertheless, these techniques require elaborate designs to improve sensitivity, as well as their multiplexing ability that is impeded by complicated operation processes combined with inferior specificity. , Hence, it is greatly desired for further development of highly sensitive and multicomponent analytical methods for amplification-free sample analysis for rapid diagnosis.…”